Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$6.74 - $11.97 $149,243 - $265,051
22,143 New
22,143 $149,000
Q1 2024

Apr 29, 2024

SELL
$4.51 - $8.92 $177,730 - $351,519
-39,408 Reduced 68.2%
18,373 $157,000
Q4 2023

Feb 07, 2024

BUY
$4.82 - $6.25 $52,118 - $67,581
10,813 Added 23.02%
57,781 $323,000
Q3 2023

Nov 02, 2023

BUY
$4.32 - $5.77 $46,306 - $61,848
10,719 Added 29.57%
46,968 $246,000
Q2 2023

Aug 07, 2023

SELL
$5.0 - $6.31 $3.33 Million - $4.21 Million
-666,743 Reduced 94.84%
36,249 $183,000
Q1 2023

May 09, 2023

SELL
$5.23 - $8.42 $352,784 - $567,962
-67,454 Reduced 8.76%
702,992 $4.04 Million
Q4 2022

Feb 09, 2023

BUY
$7.29 - $10.14 $536,398 - $746,101
73,580 Added 10.56%
770,446 $5.67 Million
Q3 2022

Nov 09, 2022

BUY
$10.02 - $26.15 $6.98 Million - $18.2 Million
696,866 New
696,866 $7.18 Million
Q2 2022

Aug 10, 2022

SELL
$6.5 - $13.68 $162,948 - $342,943
-25,069 Closed
0 $0
Q1 2022

May 09, 2022

SELL
$5.96 - $7.61 $76,097 - $97,164
-12,768 Reduced 33.74%
25,069 $178,000
Q4 2021

Feb 09, 2022

BUY
$6.96 - $9.26 $188,957 - $251,399
27,149 Added 254.01%
37,837 $285,000
Q3 2021

Nov 09, 2021

SELL
$5.71 - $7.39 $5,344 - $6,917
-936 Reduced 8.05%
10,688 $79,000
Q1 2021

May 10, 2021

SELL
$6.3 - $7.71 $11,573 - $14,163
-1,837 Reduced 13.65%
11,624 $76,000
Q4 2020

Feb 08, 2021

BUY
$6.39 - $7.76 $86,015 - $104,457
13,461 New
13,461 $98,000
Q4 2019

Feb 05, 2020

SELL
$4.34 - $5.86 $46,312 - $62,532
-10,671 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$4.93 - $5.8 $52,608 - $61,891
10,671 New
10,671 $55,000
Q4 2018

Feb 14, 2019

SELL
$4.77 - $7.9 $54,158 - $89,696
-11,354 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$6.03 - $8.34 $68,464 - $94,692
11,354 New
11,354 $78,000

Others Institutions Holding SIGA

About SIGA TECHNOLOGIES INC


  • Ticker SIGA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 73,024,096
  • Market Cap $432M
  • Description
  • SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...
More about SIGA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.